Alltian

Alltian is a clinical-stage biopharmaceutical company based in Suzhou, China, specializing in the discovery and development of innovative small molecule therapeutics. The company's primary focus is on immunology and oncology, targeting pathways with significant therapeutic potential such as TYK2. Its lead candidate, AL-001, is a highly selective TYK2 inhibitor currently in Phase 2 clinical trials for autoimmune diseases like psoriasis. Alltian leverages its proprietary drug discovery platform to create a pipeline of differentiated candidates designed to offer superior safety and efficacy. The company aims to provide transformative treatments for patients worldwide through rigorous scientific research and clinical development.